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CASE PRESENTATION
A 29-year-old woman presented with hep-
atosplenomegaly at age 6. Liver ultrasound showed
abnormal liver echogenicity, and renal ultrasound
revealed large, speckled, echodense kidneys, loss of
corticomedullary differentiation (CMD), and no discrete
cysts. She had been referred to the Nephrology Unit at
the Health Sciences Center of Memorial University at
age 12 with chronic kidney disease (CKD) and hyper-
splenism, which had resulted from presumed congenital
hepatic fibrosis, and portal hypertension. Her blood
pressure was normal; serum creatinine, 120 lmol/L
(1.4 mg/dL); the urine contained no blood or protein;
hemoglobin was 118 g/L; platelet count, 50,000 × 109/L;
and white blood cell count was between 2 and 3 × 109/L.
Until her pregnancy when she was 19 years old, she had
had stable, moderately severe, chronic renal failure and
stable hypersplenism. Prior to the pregnancy, her serum
creatinine was 125 lmol/L (1.4 mg/dL), and the estimated
creatinine clearance was 45 mL/min. Liver function tests
were normal, including albumin (38 g/L), prothrombin
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time (PT), and partial thromboplastin time (PTT); bleed-
ing time was 14 minutes. In the third trimester, she
developed preeclampsia with proteinuria, edema, and
hypertension. Serum creatinine post partum was 185
lmol/L (2.1 mg/dL). An intrauterine contraceptive de-
vice (IUCD) was inserted. By age 25 years, her estimated
creatinine clearance had decreased to 19 mL/min, and
she was taking erythropoietin alpha (Eprex) for anemia
and sodium bicarbonate for metabolic acidosis. Her blood
pressure was normal, as were serum lipid levels and di-
valent ion levels. At that time, she developed right upper
quadrant pain, lip lesions, elevation of hepatocellular en-
zyme levels, and fever. Although no bacterial diagnosis
was made, she was treated with antibiotics. No abnor-
mal ductal dilations were observed in the liver. A sin-
gle stone was visualized in the gallbladder. Gastroscopy
showed no varices in the esophagus or stomach. At age
27, she had a laparoscopic cholecystectomy following an
episode of acute cholecystitis, and a tubal ligation without
unusual bleeding. Intraoperative observation of the liver
confirmed that it was fibrotic.
Donation of a kidney from her sister (PID 52, Fig. 1)
was planned. The patient’s blood group was A, the sis-
ter’s was O, and there was no human leukocyte antigen
(HLA) match. T- and B-cell crossmatch was negative,
and both women were cytomegalovirus (CMV) nega-
tive. The transplant workup was complicated by the pres-
ence of severe neutropenia (white blood cell count, 1.5
× 109/L) and thrombocytopenia (platelet count, 33 ×
109/L). Bone marrow showed normal trilineage activity,
with no dysplastic or infiltrative features. Doppler evalu-
ation revealed enlargement of the splenic vein with flow
toward the liver. The portal vein also was large with flow
into the liver. The flow was almost all diverted into the
left hepatic vein and subsequently into a large recana-
lyzed umbilical vein. Only a small amount of flow was
identified in the right portal vein, in a normal direction.
Planned renal transplant was cancelled by the trans-
plantation service because of their fears concerning the
severity of the hypersplenism, including infection risk
when the patient was to receive immunosuppressants in
the presence of a neutrophil count of 1 × 109/L, and
bleeding risk during surgery because of thrombocytope-
nia. The patient was referred for a kidney/liver transplant.
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Fig. 1. The pedigree of the autosomal-
recessive polycystic kidney disease (ARPKD)
patient (PID 54) presented in this paper.
The liver transplant service rejected a liver transplant,
because she did not have severe parenchymal disease. By
that time, she had become sensitized. She had a CDC-
negative crossmatch with her donor but had positive flow
cytometry. Placement of a transjugular intrahepatic por-
tosystemic shunt (TIPS) was performed, in which a stent
was placed between the inferior vena cava and portal
vein, following which the white blood cell count increased
to between 2.5 and 3.5 × 109/L and platelets to between 40
and 50 × 109/L. The serum creatinine had increased to 700
lmol/L (8.0 mg/dL). The international normalized ratio
(INR), PT, and PTT were normal, but bleeding time was
greater than 15 minutes. Because of her sensitization, she
was treated with plasmapheresis and immunoglobulin-
G infusion. Hemodialysis was commenced prior to elec-
tive living donor renal transplantation. Immunizations
to meningococcus, hemophilus, and pneumococcus were
given prior to splenectomy performed at the time of
transplantation. She required 2 units of blood following
surgery. Her serum creatinine 1 week after renal trans-
plantation was 90 lmol/L (1.0 mg/dL).
The family was investigated (Fig. 1 and Appendix).
DISCUSSION
DR. PATRICK S. PARFREY (University Research Pro-
fessor, Division of Nephrology and Clinical Epidemiol-
ogy Unit, Health Sciences Center, Memorial University,
St. John’s, Newfoundland): Inherited polycystic kidney
disease is an important cause of end-stage renal dis-
ease (ESRD) and accounts for 6% of cases of ESRD
in Newfoundland [1]. Two distinct patterns of inher-
itance have been described, autosomal-dominant and
autosomal-recessive, each with different clinical charac-
teristics. Autosomal-dominant polycystic kidney disease
(ADPKD) is associated with the onset of ESRD, usually
after the reproductive years of life [2]. It is caused by
mutations in 2 genes, PKD1 and PKD2, the phenotype
associated with PKD2 being milder than that of PKD1
[2, 3]. The PKD1 gene was cloned in 1995 [4] and the
PKD2 gene in 1996 [5]. Mutations in the PKD1 gene are
responsible for the majority of cases of ADPKD. In New-
foundland, 9 of 18 families with ADPKD are linked to
PKD1 (5 of whom might have arisen from a founder mu-
tation), 4 families have PKD2 (2 of whom have the same
1640 Nephrology Forum: Autosomal-recessive PKD
mutation), one family has inherited both PKD1 and 2,
and in 4 families, the linkage is unknown [6, 7].
Autosomal-recessive polycystic kidney disease
(ARPKD) has a more dramatic and severe clinical
course than does ADPKD, causing neonatal death, CKD
during childhood, and liver disease in older survivors
[8, 9]. Its estimated incidence is 1 in 20,000 live births
[10]. The main renal manifestation of ARPKD is ectasia
and cystic dilation of the renal collecting tubules, which
remain as primitive ducts lined by undifferentiated
epithelium and sheathed with thick layers of connective
tissue [11]. Liver histology shows portal spaces enlarged
by periportal fibrosis; proliferation of biliary ducts, which
can be dilated and tortuous; and insufficient remodeling
of the primitive intrahepatic biliary system [11].
All cases of typical ARPKD have been linked to
PKHD1 locus on chromosome 6p21. In 2002, three
groups independently cloned the PKHD1 gene in the crit-
ical region on chromosome 6p21.1-p21 [12–14]. Ward et
al [12] identified a candidate gene by recognizing an or-
thologous relationship between the PCK rat locus and
the ARPKD region in humans. Onuchic et al [13] cloned
the identical gene by assembling a transcription map of
the ARPKD region and identifying a novel transcript that
was highly expressed in the region.
Two recent studies of large cohorts of ARPKD patients
reported a wide spectrum of mutations [15, 16]. Most pa-
tients did not have homozygous mutations. The mutation
detection rates were 61% and 51%. Most mutations were
private and scattered through the gene, without hot spots.
The mutation detection rate in patients with congenital
hepatic fibrosis with little or no renal disease, or Caroli
disease, was 32%.
What does today’s patient have to teach us? This
woman has ARPKD with slow progression of CKD in
childhood and adult onset of ESRD. As part of this syn-
drome, she also has congenital hepatic fibrosis, with long-
standing portal hypertension and hypersplenism, and
little evidence of severe parenchymal liver disease. The
majority of patients with ARPKD who survive the neona-
tal period survive to adulthood. The course of this pa-
tient’s renal and hepatic disease is characteristic of older
survivors of ARPKD. The major clinical problems that
arose in this patient’s care were (1) CKD; (2) pregnancy
in the presence of chronic kidney disease; (3) acute hep-
atitis of unknown cause; and (4) severe neutropenia and
thrombocytopenia prior to renal transplantation. Let’s
look at each of these problems in turn.
Major clinical problems
(1) Recently Guay-Woodford and Desmond [8] re-
ported clinical outcomes from 254 ARPKD patients from
34 North American centers, and Capisonda et al [9]
presented outcomes from 31 patients seen at a single
Canadian center from 1990 to 2000. About 30% of the
affected newborns died shortly after birth. The need for
neonatal ventilation was strongly predictive of subse-
quent development of CKD and of death. The rate of
progression of CKD was slow in older patients. In older
survivors, clinically significant morbidities related to peri-
portal fibrosis occurred, but portal hypertension did not
correlate significantly with CKD.
Fonck et al [17] reported on 16 consecutive adult pa-
tients with ARPKD who had autonomous renal function
at age 18. The mean yearly decline of creatinine clearance
was 2.9 ± 1.6 mL/min. Of the 16 patients, 94% were alive
at a mean age of 27 years. Only 2 of 16 patients had normal
renal function, 11 had CKD, one was on dialysis, 2 had
received transplants, and 4 had required portosystemic
shunts.
(2) The current patient had a fall in estimated creati-
nine clearance of 13 mL/min comparing before and after
pregnancy values, developed preeclampsia, and had an
induced pregnancy at 37 weeks. In women with CKD of
varied cause whose serum creatinine levels were = 125
lmol/L (≥ 1.4 mg/dL), about one-third developed an ac-
celerated course of renal dysfunction during pregnancy
[18, 19, 22]. In 1996, Jones and Hayslett [20] reported
that 43% of 67 women with moderate to severe renal im-
pairment due to various causes experienced a pregnancy-
related decline in renal function that persisted after
pregnancy in 31%. In 10%, the decrease in renal func-
tion was rapid and resulted in ESRD. Although the fe-
tal survival rate was 93%, 59% of the infants were born
prematurely, and intrauterine growth retardation compli-
cated 37% of pregnancies. In ADPKD patients, women
who had 3 or more pregnancies had worse renal func-
tion on long-term follow-up than those with fewer or no
pregnancies [21].
In addition to the risk of inducing a decline in re-
nal function, pregnancy brings with it a high risk of su-
perimposed preeclampsia. Between 20% and 40% of
women with some form of underlying renal disease de-
velop preeclampsia [22]. Furthermore, the increased risk
of preeclampsia also exists for subsequent pregnancies
[23]. Because of the high risk of pregnancy inducing a
decline in her renal function, because such a decline had
occurred with her first pregnancy, and because her chance
of conceiving a child with ARPKD was 50%, the patient
chose to have a tubal ligation.
(3) Recognition of patients with dilated biliary ducts is
important because biliary dilation induces risk for recur-
rent cholangitis. Cholangitis is an important considera-
tion when ARPKD patients develop acute liver disease.
However, dilated ducts were not identified by imaging
in this patient, and the clinical picture was not that of
cholangitis, but rather of viral hepatitis.
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Morbidity from congenital hepatic fibrosis is frequent
in older survivors with ARPKD. At the University of
Minnesota, 13 patients with ARPKD received a kidney
transplant, and 1 received a kidney-liver transplant, at
a mean age of 8 years (range, 1 to 22 years); the mean
follow-up was 14.5 years [24]. Congenital hepatic fibrosis
and bile duct dilation progressed during childhood. Of 14
patients, 7 developed hypersplenism, which occurred in
6 prior to renal transplantation. Of the 6 patients, 4 had
splenectomy prior to renal transplantation. Liver disease
was the cause of death in 4 of 5 patients. Of 9 surviving
patients, 5 had portal hypertension and 2 asymptomatic
biliary dilation.
When platelet counts are less than 100 × 109/L, the
prolongation of the bleeding time is usually inversely pro-
portional to the platelet count [25]. If platelet function
is normal, patients with platelet counts exceeding 50 ×
109/L will have no hemorrhagic symptoms unless they un-
dergo trauma or surgery [26]. Platelet counts below 50 ×
109/L are referred to as severe thrombocytopenia. In
some conditions associated with splenomegaly, 50% to
90% of thrombocytes can be sequestered. The splenic
pool consists of a larger proportion of megathrombo-
cytes, which are younger and possibly more effective in
hemostasis than the remainder of the circulating platelets
[27]. In addition to thrombocytopenia as a result of hyper-
splenism, the patient probably had defective adhesion of
platelets because of uremia [28]. As a result of these two
major contributions to abnormal hemostasis, the bleed-
ing time was greater than 15 minutes (reference less than
9 minutes) prior to renal transplantation. Sequestration
of leukocytes causes leukopenia. This is a major long-
term concern in renal transplantation, because treatment
with the immunosuppressants azathioprine, mycopheno-
late mofetil, and sirolimus also can induce leukopenia.
Patients with congenital hepatic fibrosis have been
treated with spleno-renal shunts prior to renal trans-
plantation [29], but the procedure is invasive, requires
lengthy surgery, predisposes to encephalopathy, and can
lead to impairment of the peritoneal cavity, precluding
peritoneal dialysis. The TIPS procedure is useful and
modestly invasive, and it has the potential to reduce por-
tal hypertension. As in the case reported by Benador et
al [30], TIPS in our patient induced a rise in platelets and
leukocytes. Nonetheless, as severe leukopenia and throm-
bocytopenia persisted, we decided that splenectomy was
necessary.
Genetic mechanisms
Let’s turn our attention to this patient’s family as well as
to the genetic mechanisms of cystic diseases. This family
history, in which 5 affected family members had congen-
ital hepatic fibrosis and 3 developed ESRD, is striking
(Appendix). Linkage analysis confirmed that the disease
segregated with markers at the ARPKD locus on chro-
mosome 6p21 and narrowed the critical region in which
the gene was located. The sibships presented here lived in
outport Newfoundland. In these small communities, the
people live in geographic isolation, depend on the fishery
for their livelihood, are segregated by religion, and pos-
sess a high coefficient of kinship [6, 29, 31]. In such genetic
isolates, one would expect a single founder mutation to
be responsible for autosomal-recessive disease. Although
genetic homogeneity was observed in sibship A, there is
genetic heterogeneity in sibship B. A similar observation
was made in the investigation of Bardet-Biedl syndrome
(BBS) in Newfoundland, where 6 different BBS geno-
types have been identified, and, in BBS6, where 3 differ-
ent mutations have been discovered [6, 32].
In addition to demonstrating that the renal-hepatic
syndrome in 5 affected members was caused by muta-
tions in the PKHD1 gene, we were able to demonstrate
that the bilateral cortical and medullary cysts seen at age
2 in PID 55 of sibship C were not caused by ARPKD. The
renal ultrasound was compatible with ADPKD rather
than ARPKD. Ultrasound imaging in 16 patients with
ARPKD revealed large kidneys in 10 patients that were
hyperechoic (N = 16) and without CMD (N = 11). Cysts
<1 cm were observed in 7 patients and cysts >1 cm in
3 [33]. By contrast, in ADPKD subjects with normal re-
nal function, features included multiple cysts of different
sizes, normal cortical echogenicity, and conserved CMD
[34], similar to the ultrasound in PID 55. As both parents
had normal renal ultrasound examinations, and the child
not only had renal cysts but also had hepatic cysts, his
disease might be the result of a de novo ADPKD mu-
tation. Linkage studies demonstrated that the proband’s
partner and her child also were carriers of ARPKD. This
was helpful information in the provision of genetic coun-
seling, as the risk of ARPKD in future offspring from this
union would be 50%.
The PKD1 gene spans more than 50 kb of genomic
DNA and is comprised of 46 exons. The gene product,
polycystin 1, is a large novel protein, with a unique mod-
ular structure and unusual hydropathy characteristics [4]
(Fig. 2). It is an integral membrane protein with a large
extracellular region, 11 transmembrane domains, and a
short tail in the cystoplasm. It is a member of an an-
cient family of proteins conserved in lower organisms,
which includes polycystin 2, the protein product of PKD2.
Polycystin 2 is a protein smaller than polycystin 1 and is
predicted to have cytoplasmic N- and C-terminals and
six transmembrane domains [5] (Fig. 2). The polycystins
probably function as Ca2+ permeable cation channels
[35]. Because mutations of PKD1 and PKD2 produced
similar clinical manifestations [2], and because PKD2
cysts have been reported with the germ line PKD2 muta-
tion, normal somatic PKD2 gene, and heterozygous mu-
tations in PKD1 gene [36], it is likely that polycystin 1
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2, and fibrocystin. (From Igarashi P, Somlo
S: Genetics and pathogenesis of PKD. J Am
Soc Nephrol 13:2384–2398, 2002, with permis-
sion.)
and 2 are part of a common biologic pathway. In fact, the
C-terminal tail of polycystin 1 physically interacts with,
and might regulate the function of, polycystin 2 [37]. Ex-
pression of polycystin 1 increases Ca2+ channel activity
of polycystin 2 [35].
The genetic mechanism of disease in ADPKD seems to
be a loss of heterozygosity caused by somatic mutations in
the wild-type allele in renal epithelial cells. This “two-hit”
hypothesis producing “recessive” disease at the cellular
level could explain the focal nature of ADPKD, in that
cysts arise from about 1% of the kidney nephrons. The
majority of PKD2 cysts have shown the germ line PKD2
mutation and different mutations distributed through-
out the somatic PKD2 gene [38]. However, this “two-
hit” model might not explain all the features of the
disease, and other genetic mechanisms such as haplo-
insufficiency or dominant-negative mutations could be
involved.
PKHD1 is a very large gene (470 kb) containing 67
exons and an open reading frame of 12,222 bp. The en-
coded protein, fibrocystin, is 4074 amino acids long and
predicted to be an integral membrane protein with a
large extracellular region and a short cytoplasmic tail [12]
(Fig. 2). Although there are some regions of homology
with other known protein domains, there is no homol-
ogy with polycystin. Mutations were distributed through
the portions of gene encoding the predicted extracel-
lular portion of the protein product [39]. Amino acid
substitutions were more commonly associated with a
nonlethal presentation, whereas chain-terminating mu-
tations were more commonly associated with neonatal
demise.
In the current family, we were able to identify one mis-
sense mutation in exon 62 of the gene proposed by Ward
et al [12], producing an amino acid change from glycine
to tryptophan in the extracellular region of the protein.
It is unclear how such an amino acid change will affect
folding or function of the protein, or how it relates to the
phenotype in sibship A. The second mutation in sibship
B was not found. Application of molecular diagnostics
to ARPKD is challenging not only because of frequent
allelic heterogeneity, but because mutations are usually
private, there is a high frequency of missense mutations,
and the PKHD1 gene is large and complex [15, 16]. There
are splice variants [13]. There might be additional exons
in the ARPKD region not identified by Ward et al [12].
Cryptic splice site mutations in an intron, or mutations
in the promoter regions, also could occur. Consequently,
detection of only about one-half of ARPKD mutations is
not surprising.
The defective cilia link
There’s another piece of the puzzle that I haven’t men-
tioned yet. Forms of cystic renal disease recently have
been associated with defects in ciliary-expressed proteins.
A cilium is a tiny hair-like appendage about 0.25 lm in
diameter that contains a microtubule bundle as a core.
Cilia, which extend from the surfaces of many cell types
and are found in many species, contribute to fluid move-
ment [40], chemoreception [41], and patterning of the
left-right body axis [42].
Only one primary cilium is expressed on the apical sur-
face of each renal epithelial cell. It is nonmotile and has
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9 peripheral doublets of microtubules. Polycystin 1 and
2 [43], and fibrocystin [44] have been localized to cilia.
Nauli et al suggested that polycystin 1 and 2 are asso-
ciated with Ca2+ influx induced by movement of cilia
and that this movement indicates a mechano-secretory
function [35, 45] (Fig. 3). Cilia might act as tubule-
size sensors, being important checkpoints in tubule
maturation that, when defective, can lead to tubule di-
lation and cyst formation (Fig. 4) [46].
Forms of PKD associated with defects in ciliary-
expressed proteins include nephronophthisis and BBS
[46]. Mutations in INVS, encoding inversion, which lo-
calized to the primary cilium, cause nephrophthisis type
2, linking renal cystic disease to the function of pri-
mary cilia and left-right axis determination [47]. Another
nephronophthisis gene, NPHP3, encodes a novel protein
that interacts with the ciliary protein nephrocystin [48].
The cpk mouse is derived from a mutation of the gene
that encodes cystin, a small protein that also localizes to
primary cilia [49].
Bardet-Biedl syndrome is characterized by abnormal-
ities of multiple organs, including the kidney, where cysts
and calyceal abnormalities occur frequently [50]. A newly
recognized BBS gene, BBS8, localizes to centrosomes
and basal bodies, and interacts with PCM1, a protein
probably involved in ciliogenesis [51]. Thus it is possible
that BBS8 either participates in ciliogenesis or mediates
communication between the cilium and the interior of the
cell. Investigation of Caenorhabditis elegans orthologues
of BBS1, BBS2, and BBS7 showed expression patterns
restricted exclusively to ciliated neurons [51].
It is likely that when one of the renal tubular cells
in a person with ADPKD acquires a somatic mutation
this inactivates the wild-type copy of the PKD gene.
Both copies of polycystin in the cell are now abnormal,
and ciliary function is defective. As a result, the mutant
cell and its daughters form a focal expansion of the re-
nal tubule [46]. The affected region continues to expand
and may seal off from the rest of the tubule creating a
cyst. Continued growth and secretion into the lumen en-
larges the cyst. In ARPKD it is likely that autosomal-
recessive inheritance of PKHD1 mutations is associated
with abnormal fibrocystin in the cilium, abnormal cil-
iary function, and consequent tubular dilation in most
nephrons.
Treatment
I’d like to turn our attention to treatment. Currently, no
treatment is available that can prevent cyst development
in humans with inherited cystic diseases. Research in an-
imal models is ongoing that is based on the belief that a
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MA: Tube morphogenesis: Making and shap-
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pathogenetic link exists between dysregulation of intra-
cellular calcium homeostasis caused by PKD1 and PKD2
mutations and an abnormal proliferative response of cyst-
derived epithelial cells to cyclic adenosine monophos-
phate (cAMP) agonists [52, 53]. Thus, pharmacologic in-
terruption of adenyl cylase receptor and tyrosine kinase
pathways might be able to diminish the rate at which cysts
grow. For example, in murine ARPKD, epidermal growth
factor receptor tyrosine kinase inhibitors were effective
in reducing cyst formation and preserving renal function
[54]. Combination therapy with WTACE2, which reduces
the availability of transforming growth factor a, provided
maximum efficacy in improving renal and biliary abnor-
malities at lower doses of the tyrosine kinase inhibitor,
thereby minimizing potential toxicity [54]. Also, peroxi-
some proliferator-activated receptor y (PPARc) agonists
can reduce the severity of PKD in PKD1 knockout mice
[55]. In the PCK rat, orthologous to ARPKD, renal cys-
tic disease development and progression were inhibited
after administration of a vasopressin V2 receptor antag-
onist; this approach reduces cAMP in the principal cells
of the collecting duct [56].
In conclusion, the patient presented here illustrates
the characteristic course of renal and hepatic disease in
ARPKD patients who survive the neonatal period. In
addition, she illustrates the risk of pregnancy in chronic
kidney disease and the difficulties associated with hyper-
splenism at the time of renal transplantation. The family
DNA studies not only confirmed linkage in 5 affected
family members to PKHD1 locus on 6p21, but also re-
vealed that another cousin with renal cysts did not have
ARPKD, but might have a de novo ADPKD mutation.
The detection of a missense mutation is compatible with
the association of these types of mutation with survival
of ARPKD patients beyond the neonatal period. The
failure to detect the second mutation demonstrates the
difficulty of mutation detection in ARPKD. Finally, re-
cent research into the mechanisms of cyst development
in inherited cystic diseases suggests a fascinating link with
ciliary dysfunction and the potential for retarding cyst de-
velopment by pharmacologic interventions.
QUESTIONS AND ANSWERS
DR. JOHN T. HARRINGTON (Dean Emeritus, Tufts
University School of Medicine, Boston, Massachusetts):
Thank you, Patrick, for an elegant elucidation of the ge-
netic and clinical aspects of ARPKD. What drives pro-
gressive renal failure in patients with recessive disease?
DR. PARFREY: The etiologic mechanisms are likely
to be different comparing autosomal-dominant to
autosomal-recessive disease. In autosomal-dominant dis-
ease, the cyst doesn’t develop until a somatic mutation
occurs in the wild-type PKD gene. That somatic muta-
tion probably occurs at different times of life, and it is
associated with clonal expansion of one particular cell. It
might be that replacement of the renal tissue by multiple
big cysts ultimately leads to CKD over time.
Patients with ARPKD are born with 2 germ-line mu-
tations, so that all cells are abnormal from the beginning,
and the ciliary sensing mechanism that determines the
width of epithelial lumens is damaged. Consequently, all
renal epithelial tubes are dilated and immature, and will
induce a fibrogenic reaction in ways that are unknown.
The fibrogenesis might be the principal mechanism lead-
ing to CKD.
DR. BRENDAN BARRETT (Professor of Medicine,
Memorial University, Newfoundland): You discussed
polycystin 1 and 2 protein interactions and how they are
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linked to function. Are there any functional interactions
between fibrocystin and other proteins that we know of?
DR. PARFREY: Research in fibrocystin is behind that of
polycystin, as fibrocystin was identified only 2 years ago.
However, a recent publication clearly demonstrates that
fibrocystin is present in the basal body of cilia [57], an
organelle necessary for normal ciliary function and pre-
sumably for sensing lumen size and controlling epithelial
cell multiplication.
DR. HARRINGTON: What are the best animal models
for assessing treatment in PKD, and what treatment is
close to market?
DR. PARFREY: The animal models are recessive models
in effect. For example, the cpk mouse is derived by mu-
tations in the gene that encodes for cystin, and the PKD1
mutant is a PKD1 knockout mouse. In terms of the ther-
apies that have been applied, the most intriguing one is
PPARc agonists, because these agents already have been
evaluated in diabetes and would be readily available for
treatment of human PKD.
DR. BRYAN CURTIS (Kidney Foundation of Canada
Fellow, Memorial University): Do you have any specific
recommendations for how we should manage patients
similar to the one discussed today to delay progression of
CKD?
DR. PARFREY: As you have heard, today’s patient had
slowly progressive CKD. Nephrologists attempt to do a
certain number of interventions in a fairly focused man-
ner. The first is blood pressure control; one should try to
lower the blood pressure to below 130/80 mm Hg. This pa-
tient didn’t have hypertension, which is unusual because
hypertension frequently occurs in these types of patients.
The second approach is blockade of the renin-angiotensin
system. Even in the absence of hypertension, the use of
angiotensin-converting enzyme inhibitors or angiotensin
II receptor blockers is well-known to slow progression of
proteinuric renal disease. A third maneuver is lipid con-
trol. Evidence suggests that lipids affect the progression
of CKD, and strong evidence indicates that the statins
would prevent the development of associated comorbid-
ity in the vascular system. So treating people with statins
to control lipid levels would be an important approach.
However, the lipid levels in today’s patient were normal.
A fourth approach is control of serum calcium and phos-
phate levels because of the link between high serum phos-
phate, high calcium × phosphate product, high parathy-
roid hormone (PTH) levels and mortality in ESRD. In
addition, there is suggestive evidence linking those risk
factors and arterial calcification, diminished arterial com-
pliance, cardiomyopathy, and cardiac death. Again, this
patient’s serum calcium and phosphate levels didn’t ap-
preciably change as she developed more progressive dis-
ease. A fifth approach, the management of anemia, is
controversial. I tend to target hemoglobin levels to 11 g/L
and give these patients erythropoietin when hemoglobin
approaches 10 g/L. Finally, the appropriate use of aspirin
and beta blockers for cardiovascular disease comorbidity
is wise. To delay the progression of CKD in all our pa-
tients, it is critical that we use a protocol-driven approach
so that they don’t escape receiving appropriate risk factor
intervention.
DR. BARRETT: You spoke a bit about the potential
pathogenetic mechanisms in the kidney that would link
these abnormal ciliary proteins to renal tubular dilation.
Could you elaborate on the potential mechanisms for the
liver disease?
DR. PARFREY: One would predict that the cell involved
in the terminal maturation of the biliary system would
have similar abnormalities to the epithelial cell in the re-
nal collecting system. It appears that’s true in that cholan-
giocytes have cilia, that the fibrocystin localizes to the
cholangiocyte cilia, and that changing the cilia within an-
imal models is associated with biliary bile duct dilation
and cyst development [58]. The initial evidence suggests
that the cellular pathogenesis of the biliary disease is sim-
ilar to that of the renal disease.
DR. SEAN MURPHY (Assistant Professor, Memorial
University): For families who have not been genetically
studied, how useful is prenatal screening with ultrasound
for either ruling out or ruling in ARPKD?
DR. PARFREY: Prenatal diagnosis of ARPKD is pos-
sible using ultrasound. Enlarged hyperechoic kidneys,
oligohydramnios, and absence of urine in the bladder can
be observed, but the renal manifestations might not be
seen until the third trimester. Oligohydramnios and the
absence of urine in the bladder are not usually appar-
ent until after 20 weeks. Furthermore, as observed in this
family, patients with ARPKD can have normal-looking
kidneys on ultrasound. Prenatal ultrasound at 18 weeks
is not a very good test because it is neither sensitive nor
specific.
DR. KULGIT GREWAL (Staff Hematologist, Health Sci-
ences Center, St. John’s, Newfoundland): What happened
to the patient after transplantation from the renal and
hypersplenism perspective?
DR. PARFREY: It is now 2 months post-transplant and
she has had no rejection episodes; her serum creatinine
is 120 lmol/L (1.4 mg/dL). She has been treated with my-
cophenolate, tacrolimus, and prednisone. Mycophenolate
can lower leukocyte counts, but her white blood cell count
is 15.6 × 109/L, and her platelet count is 360 × 109/L. She
is still anemic, with a hemoglobin of 94 g/dL. The splenec-
tomy resolved the problems with hypersplenism, and she
has been treated with conventional triple therapy without
problems.
DR. JOHN HARNETT (Professor of Medicine, Memorial
University): You reported quite a while ago that renal
transplantation in patients with hepatitis B was associated
with rapid progression of liver disease, with development
of cirrhosis, hepatic failure, and hepatoma [59]. Could
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you postulate whether the immunosuppressant regimen
that the patient is receiving for her kidney transplant will
have a beneficial or a harmful effect on her fibrotic liver
disease?
DR. PARFREY: If the liver disease is the result of a
virally mediated disease, then it seems clear that the im-
munosuppression potentiates the replication of viruses,
and the liver disease becomes more aggressive. If the fi-
brogenic reaction is occurring post transplant in response
to the cholangiocyte abnormalities and immature devel-
opment of the biliary tree, I would be very surprised if
immunosuppression would change the development of
the fibrogenesis and the expected natural course of the
liver disease.
DR. HARRINGTON: You commented that Newfound-
land is a genetic isolate. Is there opportunity for ge-
netic counseling throughout the province, not only for
ARPKD but for the other recessive diseases that also are
likely to be more common here than perhaps in other
places in Canada?
DR. PARFREY: Yes, there is opportunity for genetic
counseling, although the isolation of fishing communities
has lessened in recent decades and more out-migration
from these communities has occurred. More than one-
half of the Newfoundland population lives in communi-
ties with fewer than 2000 people. Within these communi-
ties, many families are related back several generations.
Newfoundland is not one genetic isolate but multiple iso-
lates. Consequently, different recessive diseases and dif-
ferent genotypes for the same disease occur in different
communities. We have discovered this with BBS, and with
Batten’s disease, another recessive disease with a high
frequency in Newfoundland.
DR. BARRETT: You said that in this case there wasn’t
an indication for liver transplantation because the patient
retained parenchymal hepatic function. Yet you also said
that the long-term threat to the survival of people who
have had kidney transplants might be complications of
liver disease. Could you comment on what might lead to
a further consideration of liver transplantation down the
road?
DR. PARFREY: Parenchymal liver disease is unlikely to
lead to a problem later on in people with ARPKD, so a
liver transplant is not the appropriate solution. Problems
will arise from portal hypertension, because the fibrosis
restricts the venous return of blood from the portal sys-
tem. The management of portal hypertension will be the
biggest problem.
DR. HARNETT: You demonstrated different pheno-
types across three different sibships. Even though the
numbers are small, I have the impression that the clin-
ical course appeared to be less severe in the female mem-
bers of the sibships. Is there any evidence that the gen-
der of the people affected is important in the clinical
course?
DR. PARFREY: I know of no evidence demonstrating an
association between gender and phenotype in ARPKD.
In ADPKD some have reported a worse outcome in
males [60], but that observation has not been confirmed
in the Newfoundland studies.
DR. HARRINGTON: Maybe I could ask a question of the
patient. You have obviously been sick from very early in
your life. Yet at first blush, you look wonderful today, only
a few months after transplantation. What allowed you to
maintain such a positive attitude over 3 decades?
THE PATIENT: My family has helped me keep a positive
outlook on everything, as has my doctor. I like to know
what’s going on, and if I need to have something done, I
just get on with it.
DR. PARFREY: I’d like to make a comment as well
about the patient. She has been pretty healthy and has
lived a normal life. She has had a normal child and has
been a normal mother, with good family support. She has
dealt with occasional setbacks in a pretty mature man-
ner. I think that the biggest problem she’s had is the fact
that her brother died with the same condition; that cre-
ated feelings of vulnerability. Nonetheless, she has dealt
with that and prepared herself for the transplant and the
potential complications of her condition in an admirable
manner.
APPENDIX. FAMILY STUDIES
The family was investigated (Fig. 1). Six affected chil-
dren were identified belonging to three interrelated sib-
ships (A, B, and C) living in outport Newfoundland. The
proband is PID 54 in sibship B. In sibship A, the parents
of PID 49, 50, and 51 are third cousins (PID 30 and 29).
In sibship C, the parents of PID 55 are second cousins
(PID 58 and 126). Sibship B (PID 52, 53, 54) is related to
both sibship A and C. The father of sibship B (PID 40)
is a second cousin of the father of sibship A (PID 29).
The mother of sibship B (PID 41) is a first cousin of the
father of sibship C (PID 38). Recently the proband (PID
54) married her fourth cousin (PID 161 in sibship B), and
at age 19 she had their child (PID 100).
PID 49 in sibship A, a male, presented at age 2 with
failure to thrive and marked hepatosplenomegaly. Liver
ultrasound revealed abnormal liver parenchyma and liver
cysts. Liver biopsy confirmed congenital hepatic fibrosis.
Renal ultrasound revealed a nonfunctioning left kidney
and a mild increase in echogenicity of the right kidney,
with no loss of CMD. He had a splenorenal shunt at age
13, and shortly after, he started dialysis for ESRD. He had
a renal transplant at age 14, which failed at age 25 when
he stopped taking his immunosuppressant medications.
He is alive on hemodialysis at age 28.
PID 50 in sibship A, a female, had hepatosplenomegaly
at age 1 year. Liver ultrasound revealed abnormal
parenchyma and increased echogenicity. A liver biopsy at
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age 8 showed extensive portal tract fibrosis with bile duct
proliferation consistent with congenital hepatic fibrosis.
At age 16, a splenorenal shunt was placed because of
esophageal varices. Renal ultrasound showed little or no
increase in cortical echogenicity, with preserved CMD. At
age 23, her serum creatinine was 58 lmol/L (0.7 mg/dL).
PID 51 in sibship A, a female, had hepatosplenomegaly
at age 2. Liver ultrasound showed increased echogenicity
and an enlarged spleen, and renal ultrasound disclosed
a mild increase in cortical echogenicity, maintenance of
CMD, and no renal cysts. At age 17, her serum creatinine
was 73 lmol/L (0.8 mg/dL).
PID 53 in sibship B, a brother of the proband, pre-
sented with hepatosplenomegaly at age 8. Liver ultra-
sound showed increased echogenicity and no liver cysts.
Liver biopsy revealed bile duct proliferation with mi-
nor fibrosis. Renal ultrasound showed large, speckled,
echodense kidneys, loss of CMD, and no renal cysts. He
had a splenorenal shunt at age 15, followed shortly af-
ter by a kidney transplant. He lost his transplant after 5
years and survived for 3 years on peritoneal dialysis be-
fore succumbing to complications of calciphylaxis at age
22 years.
PID 55 in sibship C, a male, had a renal ultrasound per-
formed at age 2 years because he had bilateral inguinal
hernias. The ultrasound revealed multiple cortical and
medullary cysts, with normal echogenicity and preser-
vation of renal architecture. Liver ultrasound revealed
several cysts but normal echogenicity. Renal ultrasound
examinations in both parents were normal.
Linkage analysis, using multiple microsatellite mark-
ers and single nucleotide polymorphisms (SNPs), deter-
mined that the affected individuals of sibship A and B
were linked to PKHD1 locus on chromosome 6 [ab-
stract; Davidson WS et al, Am J Hum Genet 61:A272,
1997].
Sibship A showed homozygosity by descent for
ARPKD-associated haplotype, while sibship B displayed
the ancestral disease haplotype from sibship A and an-
other disease-associated haplotype, suggesting the pres-
ence of two different mutations. The individual in sibship
C, with cortical and medullary cysts, did not have either
of the disease-associated haplotypes. The proband’s hus-
band (PID 161 in sibship B) was a carrier for one disease-
associated haplotype, and the proband’s child (PID 100)
also was a carrier; he had inherited the ancestral disease
haplotype from his mother.
In this family, the critical region for the ARPKD lo-
cus was demonstrated to be 1 cm in size, flanked cen-
tromerically by the marker D6S1024. Frost et al [abstract,
J Am Soc Nephrol 11:389A, 2000] constructed a phage 1-
derived artificial chromosome (PAC) map and screened
for new microsatellites. The critical region was narrowed
further to 624 kp between the novel marker 108C2 and
D6S1714.
In 2002, Ward et al [12] identified the PKHD1 gene.
Using this gene sequence, Wilkins (Masters of Science
Thesis, Simon Fraser University, B.C., 2002) identified a
missense mutation in exon 62, homozygous in sibship A
cases and heterozygous in sibship B. The mutation is a G
→ T nucleotide substitution resulting in the codon being
changed from GGG to TGG, and causing an amino acid
change from glycine to tryptophan. However, the second
mutation in sibship B was not found. Three known SNPs
in exons 22, 67, and 69 were found, and a previously un-
described SNP in intron 58 was identified.
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